10-Q: Mobia Medical Reports Strong Revenue Growth Post-IPO

Mobia Medical, Inc. (MOBI) announced a significant increase in revenue for the second quarter of 2026, driven by strong adoption of its Vivistim System, following its successful Initial Public Offering.

Summary

• Mobia Medical, Inc. reported a substantial increase in revenue for the second quarter and first half of 2026, driven by increased adoption of its Vivistim Paired Vagus Nerve Stimulation (VNS) System.
• The company completed its Initial Public Offering (IPO) in May 2026, raising approximately $134.0 million in net proceeds.
• Despite revenue growth, the company continued to incur significant operating losses, with a net loss of $21.0 million for the three months ended June 30, 2026, and $38.8 million for the six months ended June 30, 2026.
• Cash and cash equivalents increased significantly to $177.1 million as of June 30, 2026, following the IPO, providing sufficient liquidity for at least the next 12 months.
• The company identified a material weakness in internal control over financial reporting related to the calculation of net loss per share, with remediation efforts underway.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as cautiously optimistic, reflecting significant revenue growth and a successful IPO, but also highlighting substantial operating losses and ongoing investment needs.

Positives

• Revenue for the three months ended June 30, 2026, increased by 102.4% to $13.5 million compared to the prior year period.
• Revenue for the six months ended June 30, 2026, increased by 107.4% to $25.6 million compared to the prior year period.
• Gross margin improved to 83.2% for the three months ended June 30, 2026, and 82.8% for the six months ended June 30, 2026.
• The company successfully completed its IPO in May 2026, raising approximately $134.0 million in net proceeds.
• Cash and cash equivalents significantly increased to $177.1 million as of June 30, 2026, providing a strong liquidity position.
• The company believes its current cash position is sufficient to fund operations for at least the next 12 months.
• Two-year follow-up data from the VNS-REHAB pivotal trial, published in Neurology, showed sustained improvements in upper-limb motor impairment and function.

Negatives

• The company reported a net loss of $21.0 million for the three months ended June 30, 2026, and $38.8 million for the six months ended June 30, 2026.
• Selling, general and administrative expenses increased significantly, by 85.0% for the three months and 85.1% for the six months ended June 30, 2026, driven by increased headcount and commercialization efforts.
• Research and development costs also increased, by 60.6% for the three months and 43.2% for the six months ended June 30, 2026, reflecting continued investment in product development.
• A material weakness in internal control over financial reporting was identified concerning the calculation of net loss per share.
• The company continues to rely on third-party contract manufacturers, posing potential supply chain risks.

Risks

• Failure to manage growth effectively.
• Reliance on the success of the Vivistim System and its market adoption.
• Dependence on third-party payers for adequate coverage and reimbursement.
• Absence of a national coverage determination or local coverage determinations from CMS.
• Dependence on key personnel and key suppliers.
• Protection of proprietary technology and product liability.
• Compliance with government regulations and evolving regulatory requirements.
• Cybersecurity risks and protection of confidential information.

Future Outlook

The company expects continued investment in its commercial organization, marketing programs, and research and development to drive awareness and adoption of the Vivistim System. It anticipates increased operating expenses due to scaling operations and operating as a public company. The company believes its current cash position is sufficient for at least the next 12 months, but may seek additional financing if needed.

Management Comments

• We believe we are setting a new standard of care in chronic stroke recovery, facilitating a new treatment pathway for chronic ischemic stroke survivors with moderate to severe upper extremity impairments.
• Our mission is to redefine stroke recovery for survivors living with life-altering functional impairments by establishing Vivistim Therapy as the standard of care for chronic stroke recovery.
• We expect revenue to increase as we expand our commercial organization and sales territories, add customers and expand patient and customer awareness.
• We expect selling, general and administrative expenses to continue to increase in absolute dollars as we expand our commercial organization...

Industry Context

StockSavvy.ai notes that Mobia Medical operates in the growing neuro-rehabilitation market, specifically addressing the significant unmet need in chronic stroke recovery. The company's Vivistim System is positioned as a first-in-class device for upper extremity impairments, facing competition from traditional therapy methods and other emerging technologies in the broader medical device sector.

Comparison to Industry Standards

• The company's revenue growth of over 100% in the reported periods significantly outpaces the typical growth rates for established medical device companies, reflecting its early-stage commercialization and market penetration efforts.
• The gross margin of over 80% is strong and aligns with or exceeds industry benchmarks for specialized medical devices, indicating efficient production and pricing power.
• The significant operating loss, while common for growth-stage medical device companies investing heavily in R&D and commercialization, is a key area for investors to monitor, especially in comparison to peers who may be closer to profitability or have different funding structures.
• The successful completion of an IPO at a $15.00 per share price point is a positive indicator, reflecting investor confidence in the company's technology and market potential, though the subsequent stock performance will be a critical benchmark.

Legal Proceedings

• Management is not aware of any material legal proceedings that would have a material effect on its financial position, results of operations, or cash flows.

Related Party Transactions

• During the six months ended June 30, 2026, Exceller Hunt and the Curnes Fund purchased approximately $4.0 million and $2.1 million, respectively, of convertible promissory notes.
• Entities affiliated with U.S. Venture Partners, GPG Healthcare Opportunities Fund, LLC, Osage University Partners, and Casey Tansey also participated in the convertible promissory note issuance.
• During the six months ended June 30, 2025, Exceller Hunt and the Curnes Fund acquired shares of Series F redeemable convertible preferred stock.
• Entities affiliated with U.S. Venture Partners, GPG Healthcare Opportunities Fund, LLC, and Osage University Partners participated in Series E and F preferred stock financings.

Stakeholder Impact

• Shareholders: The successful IPO provides liquidity and potential for future growth, but ongoing losses and the need for future financing could lead to dilution.
• Employees: The company is expanding its commercial organization, suggesting potential for new job opportunities. Share-based compensation is a significant component of employee incentives.
• Customers (Hospitals/Therapy Sites): Increased adoption of the Vivistim System offers a new treatment option for stroke survivors, potentially improving patient outcomes.
• Payors (Insurance Companies, Medicare/Medicaid): The company is actively working to secure and expand reimbursement coverage, which will impact the accessibility and cost of the Vivistim System for patients.

Next Steps

• Continue to invest in and grow the commercial organization to scale the team and broaden geographic reach.
• Expand marketing programs to increase awareness and adoption of the Vivistim System.
• Continue to invest in research and development, including product improvements and next-generation versions of the Vivistim System.
• Support new clinical studies and expand clinical evidence to validate product efficacy and support coverage decisions.
• Continue to work with healthcare providers to integrate Vivistim Therapy into standard care pathways.
• Focus on expanding payor coverage and facilitating streamlined prior authorization processes.

Key Dates

Recommendation

Mobia Medical has demonstrated impressive revenue growth and successfully navigated an IPO, indicating strong market reception for its Vivistim System. However, the substantial and increasing operating losses, coupled with significant investments in R&D and commercial expansion, warrant a cautious approach. While the future outlook is positive due to the unmet need in stroke recovery and the company's first-mover advantage, the path to profitability remains long and capital-intensive. Investors should monitor the company's ability to scale effectively, manage expenses, and secure future funding without excessive dilution. Therefore, a 'hold' recommendation is appropriate, balancing the growth potential against the inherent risks and ongoing financial requirements.

Keywords

Mobia Medical, Vivistim System, Stroke Recovery, Vagus Nerve Stimulation, Medical Device, IPO, Neurology, Reimbursement